BioNTech SE (NASDAQ:BNTX) reported a narrower loss for the second quarter on Monday.

The company posted a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, versus a loss of 3.36 euros reported a year ago, compared to beating the consensus loss of $2.42 per share.

The COVID-19 vaccine maker reported sales of $295.69 million (260.8 million euros), compared to 128.7 million euros a year ago, beating the consensus of $147.90 million.

BioNTech reaffirmed its fiscal year 2025 guidance of 1.7 billion-2.2 billion euros compared to the consensus of 2.05 billion euros and revenue phasing primarily …

Full story available on Benzinga.com